Off-Label Indicators

  • by: |
  • 11/27/2006
According to a Interactive health-care poll U.S. adults are divided on whether doctors should be allowed to prescribe drugs to treat diseases or conditions other than those for which they have been approved.

45% of those surveyed say doctors "should be allowed to decide which prescription drug treatments to use with their patients regardless of what diseases they have or have not been approved for by the FDA," compared with 46% who said this shouldn't be allowed.

Frighteningly, nearly two-thirds say they would agree to prohibit off-label prescribing unless it is part of a clinical trial, while 28% wouldn't support such limitations. Attention must be paid – this is the slippery slope that the Apostles of Evidence-based Medicine would have us follow – to disastrous consequences.

Fortunately, when put into the appropriate perspective, Americans don't want to hamper innovation. 55% believe that if doctors aren't allowed to prescribe freely that it will be much more difficult to find new and innovative ways to treat diseases vs. 35% who disagree.

More than two-thirds believe drug companies shouldn't be “allowed to encourage” off-label use vs. 12% who disagree and 20% who aren't sure. Perhaps a better way to have framed that question would have been to have asked if drug companies should be “allowed to share valid clinical information” about off-label use?

One wonders if the pollsters screened out as respondents patients with cancer, multiple sclerosis, etc. and their family members. And, if not, how that segment answered the questions.

For that we do not need a research project – we need a robust Critical Path program.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog